Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2109 vs Darzalex Faspro in Relapsed/Refractory Multiple Myeloma
NCT06742138Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Therapeutic Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, randomised, double-blind trial of QL2109 in multiple myeloma (MM) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percentage of Participants With Very Good Partial Response (VGPR) or Better at Week 24. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
QL2109
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06742138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742138.